EAG Scientists Present Research at SciX 2024
EAG Scientists present research at SciX 2024 focused on compositional analysis and provenience studies of natural iron oxides pigments.
Introducing EAG Laboratories
EAG Inc., a global scientific services company that serves a vast array of technology- and life-science-related industries, today announced that it has combined its 11 market-facing brands under a singular entity: EAG Laboratories. Following multiple acquisitions in recent years, the move is designed to bring together broad capabilities in the materials, engineering and life sciences sectors. EAG Laboratories will leverage scientific talent in its 20 locations in the U.S., Europe and Asia-Pacific regions, strengthening its offering for each of the vertical markets it serves.
“Over the last decade, EAG has quietly added capabilities through complementary acquisitions and service line expansions in the high-growth contract research and testing space,” stated Siddhartha Kadia, president and CEO, EAG Laboratories. “We’ve built a problem-solving culture in which our scientists and engineers go beyond simply delivering data; they interpret results and find answers that support our clients’ commercial success. That is something today’s technology-driven companies need from their outsourcing partners, and it makes EAG unique in the scientific services arena. By unifying multidisciplinary expertise under one brand, we simplify delivery of our services to enhance our customer relationships.”
EAG Laboratories brand
Moving forward, the following brands will be known as EAG Laboratories: Evans Analytical Group, ABC Laboratories, Chemir Analytical Services, SEAL Laboratories, PTRL West, PTRL Europe, Wildlife International, Shiva Technologies, NanoScience, Accurel and MEFAS. EAG Laboratories offers an extensive range of testing, analytical and characterization services (including environmental testing, custom synthesis and radiolabeling, crop sciences, drug development, materials testing, contaminant identification, failure analysis, engineering services, consulting and expert testimony) to companies operating across a broad range of markets, including pharmaceutical, biopharmaceutical, medical devices, crop protection, aerospace, defense, semiconductor, wearables and other consumer products, among others.
“Since day one, we’ve pursued our vision of being a world-class testing and analytical services company by adding more and more expertise and capability to a company we believed to have the best and brightest people in the industry,” said Randy Paulson, a managing principal at Odyssey Investment Partners, EAG Laboratories’ majority owner. “We now have expanded services that match all our clients’ testing and analysis requirements, and also have been aggressive in augmenting our executive team in the last 18 months. We have all of the pieces in place to help grow EAG Laboratories, creating even more value for our worldwide customer base.”
EAG Laboratories’ most recent acquisition came in July 2015, adding Analytical Bio-Chemistry Laboratories (ABC Laboratories) to its portfolio. Offering development of cGMP and GLP-compliant testing capabilities for small- and large-molecule therapies and medical devices, ABC Laboratories strengthened EAG’s existing U.S. and European testing, analysis and characterization service offerings for the agrochemical, pharmaceutical and industrial chemical markets.
Prior to ABC Laboratories, EAG augmented its testing, analysis and characterization service offerings in 2013 through the acquisition of Wildlife International (critical, higher-tier ecotoxicology and environmental fate testing services) to complement earlier acquisitions of PTRL West and PTRL Europe, both leaders in analytical chemistry, residue analysis, environmental fate and metabolism testing for pesticides.
n 2012, EAG Laboratories acquired leading metallurgical analysis laboratory SEAL Labs, bringing together two companies with industry-leading expertise in materials characterization services for electronics, aerospace, defense, industrial and medical devices companies.
Other notable acquisitions include that of Chemir Analytical Services in 2011. The addition of Chemir added multiple industry-leading analytical capabilities used for a range of applications, from determining the source of product failures to helping defend a patent infringement case. Chemir also added analytical services for the polymer, paint, coatings, adhesive and sealant industries, and has been at the forefront of helping to develop innovative painting and coatings technologies. The acquisition also included analytical services such as stability programs, extractables and leachables, bioanalysis and custom synthesis.
“Since our acquisition by Odyssey Investment Partners in 2008, we have been following an aggressive acquisition strategy to significantly augment our testing, analysis and characterization services offerings. We’ve quietly amassed some of the world’s most trusted names in contract research, development and testing. While the puzzle is not yet complete, our clients see us as being a global scientific services company with industry-leading expertise in testing, analysis and characterization services bringing significant customer value to multiple markets,” concluded Kadia.
# # #
About EAG Laboratories
EAG Laboratories is a global scientific services company serving clients across a vast array of technology-related industries. Through multidisciplinary expertise in the life, materials and engineering sciences, EAG Laboratories helps companies innovate and improve products, ensure quality and safety, protect intellectual property and comply with evolving global regulations. EAG Laboratories employs 1,200+ employees across 20 laboratories in seven countries, serving more than 7,000 clients worldwide. Visit www.eag.com for more information.
EAG Laboratories is a trade name of EAG Inc., majority owned by Odyssey Investment Partners LLC, a leading private equity firm with more than $3.5 billion in capital under management. Odyssey makes majority, control investments primarily in established middle-market industrial manufacturing and business services companies in a variety of industries. Further information regarding Odyssey Investment Partners can be found at www.odysseyinvestment.com.
More content you might like...
Frequently Asked Questions About In Vitro Irritation and Cytotoxicity Testing
Biocompatibility assessments are a battery of tests performed to evaluate a product, medical device, or other material for the risk of biological hazards.
The Conspicuous Case of the Missing T0 in ISO 10993-5 Cytotoxicity Testing
In the world of medical device safety testing, ISO 10993-5 plays a crucial role. A key aspect of this, which is sometimes overlooked in certain studies, is the T0 time point, or time zero.
Rare Earth Elements Aren’t So Rare After All
The term ‘rare earth elements’ (REEs) is a misnomer and better refers to the relatively rare ores REEs are extracted from; rare earth elements are all around us!